Trial in progress: linvoseltamab, a BCMAxCD3 bispecific antibody, in a Phase 1b multi-cohort study of combination regimens for patients with relapsed/refractory multiple myeloma

被引：0

作者：

Rodriguez-Otero, Paula ^{[1
]}

Joseph, Nisha ^{[2
]}

Kumar, Shaji ^{[3
]}

Leleu, Xavier ^{[4
]}

Manier, Salomon ^{[5
]}

Dimopoulos, Meletios ^{[6
]}

Mateos, Maria-Victoria ^{[7
]}

Oriol, Albert ^{[8
,9
]}

Bumma, Naresh ^{[10
]}

Gong, Weiying ^{[11
]}

Roy, Pourab ^{[11
]}

Lorenc, Karen Rodriguez ^{[11
]}

Kroog, Glenn ^{[11
]}

Sarkaria, Shawn ^{[11
]}

机构：

[1] Univ Navarra Clin, CIMA, CIBERONC, IDISNA, Pamplona, Spain

[2] Emory Univ, Winship Canc Inst, Atlanta, GA USA

[3] Mayo Clin, Rochester, MN USA

[4] Hosp Mileterie, Poitiers, France

[5] Univ Lille, Ctr Hosp Univ Lille, Lille, France

[6] Natl & Kapodistrian Univ Athens, Athens, Greece

[7] Univ Hosp Salamanca, IBSAL, CIC, CIBERONC, Salamanca, Spain

[8] Catalan Inst Oncol, Hosp Germans Trias i Pujol, Badalona, Spain

[9] Josep Carreras Inst, Hosp Germans Trias i Pujol, Badalona, Spain

[10] Ohio State Univ, Comprehens Canc Ctr, Columbus, OH USA

[11] Regeneron Pharmaceut Inc, Tarrytown, NY USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-046

引用

页码：S60 / S60

页数：1